Bedrijfsvoering Pfizer, Inc.

PFE

US7170811035

Farmaceutische producten

Beurs gesloten - Nyse Andere beurzen 22:01:13 16-09-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
30,07 ^USD	+2,73%		+2,24%	+4,45%

16/09	Pfizer' geneesmiddel tegen cachexie bij kanker bereikt hoofddoel in fase 2-studie	MT
16/09	Pfizer zegt dat BRAFTOVI in combinatie met MEKTOVI klinisch significante respons op lange termijn laat zien bij patiënten met longkanker	MT

Uitvoerend comité: Pfizer, Inc.

Bedrijfsleider

Beklede functiesVan

Albert Bourla

62 jaar

Chief Executive Officer

01-01-2019

Mikael Dolsten

65 jaar

Chief Tech/Sci/R&D Officer

01-12-2010

Payal Sahni Becher

Human Resources Officer

01-01-1997

Aida Habtezion

Chief Tech/Sci/R&D Officer

01-01-2021

Gordon Loh

Comptroller/Controller/Auditor

01-03-2020

Jennifer Damico

56 jaar

Comptroller/Controller/Auditor

01-03-2020

Lidia Fonseca

55 jaar

Chief Tech/Sci/R&D Officer

Christopher J. Stevo

Investor Relations Contact

19-07-2021

François-Maurice Garnier

62 jaar

General Counsel

01-01-2003

Margaret M. Madden

General Counsel	-
Corporate Secretary	-

Douglas Lankler

58 jaar

General Counsel

01-12-2013

Rady Johnson

63 jaar

Compliance Officer

01-12-2013

Jeff Settleman

Chief Tech/Sci/R&D Officer

01-07-2019

Bryan Supran

General Counsel

01-04-2016

Annaliesa Anderson

Chief Tech/Sci/R&D Officer

01-01-2007

David Denton

59 jaar

Director of Finance/CFO

02-05-2022

Maria Rivas

60 jaar

Chief Tech/Sci/R&D Officer

01-09-2022

Susan Rienow

45 jaar

Sales & Marketing

Samenstelling van de raad van bestuur: Pfizer, Inc.

Directeur

RadenVan

Albert Bourla

62 jaar

Executive Committee Chair

01-01-2020

Scott Gottlieb

51 jaar

Executive Committee	27-06-2019
Governance Committee	29-10-2019
Nominating Committee	29-10-2019
Compensation Committee	04-02-2020
Governance Committee Chair	04-02-2020
Nominating Committee Chair	04-02-2020

Ronald Blaylock

64 jaar

Compensation Committee	23-02-2017
Governance Committee	01-01-2001
Nominating Committee	01-01-2001
Compensation Committee Chair	17-10-2007
HR Committee Chair	17-10-2007
Audit Committee	23-02-2017

Joseph Echevarria

66 jaar

Audit Committee	25-06-2015
Governance Committee	01-04-2016
Nominating Committee
Finance Committee Chair
Executive Committee	25-06-2015
Governance Committee Chair	25-06-2015

Suzanne Johnson

66 jaar

Executive Committee	01-09-2007
Audit Committee Chair	01-09-2007
Governance Committee	20-01-2022
Nominating Committee	20-01-2022
Compensation Committee Chair	20-01-2022

Cyrus Taraporevala

58 jaar

Audit Committee	27-06-2024
Compensation Committee	27-06-2024
Nominating Committee	14-12-2023

Jim Smith

64 jaar

Audit Committee	26-06-2014
Executive Committee	26-06-2014
Compensation Committee Chair	26-06-2014

Helen Hobbs

71 jaar

Executive Committee	12-12-2011
Governance Committee	18-04-2012

James Quincey

59 jaar

Executive Committee Chair	24-04-2019
Compensation Committee	27-02-2020

Sue Desmond-Hellmann

66 jaar

Governance Committee

01-01-2020

Dan Littman

71 jaar

Governance Committee

05-03-2018

Shantanu Narayen

60 jaar

Executive Committee

27-09-2013

Susan Hockfield

73 jaar

Director/Board Member	04-03-2020
Independent Dir/Board Member	04-03-2020

Recente benoemingen: Pfizer, Inc.

Rocket Pharmaceuticals, Inc. Benoemt Mikael Dolsten tot lid van de Raad van Bestuur	11/09	CI
Pfizer benoemt Elif Aral tot regionaal president voor het Midden-Oosten, Rusland en Afrika (MERA)	05/09	CI
Volcano Spring International Holdings Limited kondigt benoeming aan van Zheng Jingwen tot niet-uitvoerend bestuurder	02/09	CI
OS Therapies Incorporated benoemt Borys Shor in de Adviesraad voor Antilichaam Geneesmiddelconjugaten (ADC)	22/08	CI
Genmab A/S kondigt wijzigingen in de directie aan	16/08	CI
Oculis Holding AG benoemt Sharon Klier tot Chief Development Officer	15/08	CI
Atara Biotherapeutics, Inc. kondigt wijzigingen in CEO aan, met ingang van 9 september 2024	12/08	CI

Meer nieuws

Voormalige zaakvoerders en bestuurders: Pfizer, Inc.

Insider

Beklede functies

VanTot

Frank D'Amelio

Director of Finance/CFO	01-09-2007	01-06-2020
Corporate Officer/Principal	01-06-2020	01-12-2021

Wyllie Cornwell

Director/Board Member	01-02-1997	16-11-2020
Independent Dir/Board Member	01-02-1997	16-11-2020

James Kilts

Director/Board Member	01-09-2007	16-11-2020
Independent Dir/Board Member	01-09-2007	16-11-2020

Loretta V. Cangialosi

Comptroller/Controller/Auditor

01-03-2020

Dennis Ausiello

Director/Board Member	01-12-2006	25-04-2019
Chairman	25-05-2011	25-05-2011
Independent Dir/Board Member	23-04-2015	25-04-2019

George A. Lorch

Director/Board Member	01-06-2000	23-04-2015
Chairman	14-12-2010	13-12-2011
Independent Dir/Board Member	05-04-2011	23-04-2015

M. Anthony Burns

Director/Board Member	01-01-1988	19-12-2013
Independent Dir/Board Member	24-05-2011	19-12-2013

William Herbert Gray

Director/Board Member	01-06-2000	01-07-2013
Independent Dir/Board Member	24-05-2011	01-07-2013

Michael Brown

Director/Board Member	01-01-1996	01-04-2012
Independent Dir/Board Member	24-05-2011	01-04-2012

Briggs Morrison

Chief Tech/Sci/R&D Officer

01-10-2007

01-12-2011

Neil Gibson

Corporate Officer/Principal

01-01-2007

01-01-2011

Jeffrey Kindler

Director/Board Member	01-03-2005	31-07-2006
Chief Executive Officer	31-07-2006	05-12-2010
Chairman	19-12-2006	05-12-2010
General Counsel	01-01-2002	31-07-2006
Corporate Officer/Principal	01-01-2002	01-03-2005

Richard Bagger

Public Communications Contact

01-01-2006

01-01-2010

John LaMattina

Corporate Officer/Principal

01-01-2004

01-12-2008

Allen Waxman

General Counsel

01-01-2003

11-03-2008

David Shedlarz

Director/Board Member	01-07-2005	01-12-2007
Director of Finance/CFO	01-01-1999	01-07-2005
Corporate Officer/Principal	01-07-2005	01-12-2007

Alan Levin

Director of Finance/CFO	01-01-1987	01-09-2007
Treasurer	01-01-1987	01-09-2007

Ruth Simmons

Director/Board Member

01-01-1997

26-04-2007

Stanley O. Ikenberry

Director/Board Member

01-10-2005

22-03-2007

Karen Katen

Director/Board Member

01-01-1974

01-01-2007

Eliot Forster

Corporate Officer/Principal

01-01-1996

01-01-2007

Sharon Real

Corporate Officer/Principal

01-01-2000

01-01-2006

Jean-Paul Vallès

Director/Board Member

01-01-1980

23-06-2005

Yvonne R. Jackson

Human Resources Officer

01-07-2002

01-06-2005

Franklin Raines

Director/Board Member	01-10-1998	28-04-2005
Director/Board Member	01-01-1993	01-01-1996

Yoshihiro Toyohara

Corporate Officer/Principal

01-01-2003

01-01-2005

Brian Goldberg

Corporate Officer/Principal

01-06-2002

30-09-2004

William J. Creelman

Comptroller/Controller/Auditor

01-01-2003

01-01-2004

Lynne E. Weissberger

Director/Board Member

01-04-1996

01-12-2003

William H. D. Horton

Public Communications Contact

01-07-2002

01-09-2003

Pat Parr

Corporate Officer/Principal

01-01-1997

01-04-2003

George Milne

Director/Board Member	01-01-1984	01-01-1985
Chief Tech/Sci/R&D Officer	01-01-1970	01-01-2002

Warren R. Winter

Chief Tech/Sci/R&D Officer

01-01-1986

31-12-2001

Emmett Cunningham

Corporate Officer/Principal

31-12-2001

Wendell Wierenga

Corporate Officer/Principal

01-01-1990

01-07-2000

Michael Berendt

Corporate Officer/Principal

01-01-1982

01-01-2000

Richard G. Minicus

Corporate Officer/Principal

30-12-1998

John T. Boris

Corporate Officer/Principal

02-01-1988

01-01-1998

Dilip J. Mehta

Corporate Officer/Principal

01-01-1982

Mark A. Braman

Corporate Officer/Principal

01-01-1984

01-01-1996

Jonathan R. McGrath

Chief Tech/Sci/R&D Officer

01-01-1990

01-01-1995

Henrik Rasmussen

Corporate Officer/Principal

01-01-1989

01-12-1994

Andrew B. McCormick

Public Communications Contact

01-01-1993

Robert Cohen

Corporate Officer/Principal

01-01-1981

01-01-1992

Gene Clapp

Corporate Officer/Principal

31-12-1987

Sylvia Montero

Human Resources Officer

01-01-1978

Dennis J. Block

Corporate Officer/Principal

John Nicastro

Sales & Marketing

Mike E. Pape

Corporate Officer/Principal

Michael Petrarca

Corporate Officer/Principal

Nancy Ramamurthi

Corporate Officer/Principal

Leonard C. Stephens

Human Resources Officer

Jean-Michel Hotton

Corporate Officer/Principal

Raul E. Kohan

Comptroller/Controller/Auditor

Daniel Cushing

Corporate Officer/Principal

Andrew Hertzmark

Corporate Officer/Principal

Robert L. Mallett

Public Communications Contact

Ali Shirazi

Corporate Officer/Principal

Gabriela G. Cezar

Corporate Officer/Principal

Shreya Prudlo

Public Communications Contact

Robert W. Norton

Corporate Officer/Principal

John W. Mitchell

Corporate Officer/Principal

David McGibney

Corporate Officer/Principal

Tyana Kurtz

Sales & Marketing

Pierre E. G. Etienne

Chief Operating Officer

Theodore Matthew Thome

Corporate Officer/Principal

Richard A. Lotti

Corporate Officer/Principal

Peter Rost

Corporate Officer/Principal

Malcolm Kahn

Comptroller/Controller/Auditor	-	-
Sales & Marketing	-	-

Albert Michael Davis

Corporate Officer/Principal

Jay Lichter

Corporate Officer/Principal

Robert H. Driver

Corporate Officer/Principal

Steve Kennedy

Corporate Officer/Principal

Alan Lang

Corporate Officer/Principal

Andrew McDonald

Corporate Officer/Principal

Stephen Arneric

Corporate Officer/Principal

Anup Arora

Corporate Officer/Principal

Howard Zauberman

Corporate Officer/Principal

Donald R. Sellers

Corporate Officer/Principal

James W. Larson

Human Resources Officer

Charles L. Hardwick

Public Communications Contact

01-01-1966

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	39
Vrouw	10

Waarvan leden van het uitvoerend comité

Man	13
Vrouw	5

Waarvan bestuurders

Man	12
Vrouw	1

ESG Refinitiv

C+

Milieu

Emissies

Innovatie

Gebruik van middelen

Bedrijfsvoering

MVO-strategie

Beheer

Aandeelhouders

Controverse

Pfizer, Inc. is de grootste farmaceutische groep ter wereld. De netto-omzet is als volgt over de productfamilie verdeeld: - producten voor eerstelijnszorg (72,8%): geneesmiddelen voor interne geneeskunde, vaccins, geneesmiddelen voor de preventie en behandeling van Covid-19, antivirale middelen, op mRNA gebaseerde producten, enz; - specialistische zorgproducten (13,8%): geneesmiddelen die worden gebruikt in de immunologie, in ziekenhuizen en voor de behandeling van zeldzame ziekten, ontstekingsremmende geneesmiddelen, enz; - oncologische producten (12,1%); - overige (1,3%). Eind 2022 had de groep wereldwijd meer dan 35 productielocaties. De netto-omzet is geografisch als volgt verdeeld: de Verenigde Staten (42,3%), Europa (21,9%) en overige (35,8%).

Werknemers

88.000

Sector

Farmaceutische producten

Agenda

29-10-2024 - Q3 2024 Cijferpublicaties (schatting)

Meer informatie over het bedrijf